Topic: Type 2 diabetes


AstraZeneca | Cotadutide

AstraZeneca is testing cotadutide in several clinical trials spanning a range of indications, including heart failure, Type 2 diabetes and kidney failure. Crunching data from one of those trials found that cotadutide reduced liver fat in patients with diabetes who were also overweight or obese.